Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21866486 | 0.74 | — | — | |
| SCHEMBL496774 | 0.70 | — | — | |
| SCHEMBL418534 | 0.69 | PTGS1 (0.53) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| Hydrochloric Acid SCHEMBL5066620 | 0.69 | — | — | |
| SCHEMBL565251 | 0.69 | USP2 (0.57) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL1687008 | 0.69 | — | — | |
| SCHEMBL19113262 | 0.68 | ALDH1A1 (0.33) | LMNA | |
| SCHEMBL30609 | 0.67 | PTGS1 (0.43) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL9743727 | 0.67 | PTGS1 (0.43) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL28038731 | 0.67 | PTGS1 (0.50) | PTGS1PDE4ALMNASLC6A6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124793-B2 | Derivatives of ethylene methanedisulfonate as cancer chemotherapeutic agents | CRONYN MARSHALL W (US) | 2012-02-28 | — | — | US | disclosed |
| US-20090176805-A1 | DERIVATIVES OF ETHYLENE METHANEDISULFONATE AS CANCER CHEMOTHERAPEUTIC AGENTS | CRONYN MARSHALL W | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176805-A1 | DERIVATIVES OF ETHYLENE METHANEDISULFONATE AS CANCER CHEMOTHERAPEUTIC AGENTS | MGMT, ETV6, EI24 | PTGS1 504/4885PDE4A 4207/4885LMNA 4554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.